Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 1/20 | 0.33 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3126136 | 0.97 | FFAR3 (0.72) | FFAR3ALDH1A1SMN1; SMN2CYP2C19CETP | |
| SCHEMBL11922843 | 0.97 | FFAR3 (0.72) | FFAR3ALDH1A1SMN1; SMN2CYP2C19CETP | |
| SCHEMBL60503 | 0.97 | FFAR3 (0.72) | FFAR3ALDH1A1SMN1; SMN2CYP2C19CETP | |
| SCHEMBL13075808 | 0.97 | FFAR3 (0.72) | FFAR3ALDH1A1SMN1; SMN2CYP2C19CETP | |
| SCHEMBL18449 | 0.97 | FFAR3 (0.72) | FFAR3ALDH1A1SMN1; SMN2CYP2C19CETP | |
| SCHEMBL25213839 | 0.97 | FFAR3 (0.72) | FFAR3ALDH1A1SMN1; SMN2CYP2C19CETP | |
| SCHEMBL14627497 | 0.97 | FFAR3 (0.72) | FFAR3ALDH1A1SMN1; SMN2CYP2C19CETP | |
| SCHEMBL13341342 | 0.97 | FFAR3 (0.72) | FFAR3ALDH1A1SMN1; SMN2CYP2C19CETP | |
| SCHEMBL19322861 | 0.97 | FFAR3 (0.72) | FFAR3ALDH1A1SMN1; SMN2CYP2C19CETP | |
| SCHEMBL13075127 | 0.97 | FFAR3 (0.72) | FFAR3ALDH1A1SMN1; SMN2CYP2C19CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670446-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030185-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | WO | claimed |
| EP-0629634-B1 | Process for the preparation of taurocholic acids | SANOFI SA (FR) | 1998-02-25 | — | — | EP | claimed |
| US-5565587-A | TREATING CHOLANIC ACID WITH ACID CHLORIDE IN PRESENCE OF TERTIARY AMINE, TREATING RESULTING MIXED ANHYDRIDE WITH TAURINE | SANOFI (FR) | 1996-10-15 | — | — | US | claimed |
| CN-119414507-A | Resin composition, compound, substrate, optical filter, solid-state imaging device, and optical sensor device | JSR株式会社 | 2025-02-11 | — | — | CN | disclosed |
| CN-113292807-B | Resin composition, compound, substrate, optical filter, solid-state imaging device, and optical sensor device | JSR株式会社 | 2024-11-22 | — | — | CN | disclosed |
| CN-117757205-A | Resin composition, compound, substrate, optical filter, solid-state imaging device, and optical sensor device | JSR株式会社 | 2024-03-26 | — | — | CN | disclosed |
| CN-113292807-A | Resin composition, compound, base material, optical filter, solid-state imaging device, and optical sensor device | JSR株式会社 | 2021-08-24 | — | — | CN | disclosed |
| US-9908848-B2 | Amide derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-06 | — | — | US | disclosed |
| US-9656945-B2 | 3-acyl-ingenols II | LEO LABORATORIES LIMITED (IE) | 2017-05-23 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160068483-A1 | AMIDE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-10 | — | — | US | disclosed |
| US-4339591-A | Process for the production of caboxylic acid cyanides | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1982-07-13 | — | — | US | disclosed |
| US-4324744-A | PHOTOINITIATORS | BASF AKTIENGESELLSCHAFT (DE) | 1982-04-13 | — | — | US | disclosed |
| US-4265723-A | UNSATURATED POLYESTERS OR VINYL ESTERS OF POLYEPOXIDES AND A UV SENSITIZER OF AN ACYL PHOSPHINE OXIDE | BASF AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| US-4191770-A | ANTIULCER AGENTS, ANTISECRETORY AGENTS | KALI-CHEMIE PHARMA GMBH (DE) | 1980-03-04 | — | — | US | disclosed |
| US-4122116-A | HERBICIDES | DEUTSCHE GOLD- UND SILBER- SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1978-10-24 | — | — | US | disclosed |
| US-4108877-A | REACTING ACYL HALIDE WITH COPPER CYANIDE WITH HEATING IN THE PRESENCE OF A CARBOXYLIC ACID NITRILE AND AN ORGANIC SOLVENT | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1978-08-22 | — | — | US | disclosed |
| US-4108875-A | REACTING ACYL HALIDE WITH AN ALKALI METAL CYANIDE AND A COPPER(I) SALT IN THE PRESENCE OF A CARBOXYLIC ACID NITRILE WITH HEATING | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1978-08-22 | — | — | US | disclosed |
| US-3987059-A | ALKYL LITHIUM, CYCLIZATION, DEMETALLIZATION | SANDOZ, INC. (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068483-A1 | AMIDE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | NAAA, FAAH, FAAH2 | CACNA2D1 3028/4885HSD11B1 1954/4885FFAR3 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.